Intranasal tetrandrine temperature-sensitive gel for treatment of post-traumatic stress disorder
10.16438/j.0513-4870.2019-0510
- VernacularTitle:治疗创伤后应激障碍的粉防己碱鼻用温敏凝胶研究
- Author:
Lu-lu PANG
1
;
Yan GAO
2
;
Li-hua ZHANG
1
;
Jin-qiu MA
1
;
Si-qing ZHU
3
;
Lin ZHU
2
;
Li-na DU
4
;
Yi-guang JIN
3
Author Information
1. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China
2. Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China
3. Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; Anhui Medical University, Hefei 230032, China
4. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing 100850, China; Anhui Medical University, Hefei 230032, China
- Publication Type:Research Article
- Keywords:
post-traumatic stress disorder;
tetrandrine;
temperature-sensitive gel;
nasal administration;
behavior
- From:
Acta Pharmaceutica Sinica
2019;54(9):1680-1687
- CountryChina
- Language:Chinese
-
Abstract:
The traditional systemic treatment of post-traumatic stress disorder (PTSD) requires a long time period for an effect and has obvious side effects. In this study, tetrandrine temperature-sensitive gel (TTG) was prepared for treatment of PTSD in mice by nasal administration. TTG was prepared with poloxamer as matrix, the gelation temperature was suitable (<32 ℃) and the gelation time was short (1.32 min). Rheology experiments demonstrated that TTG has temperature sensitivity. In vivo imaging system of small animals proved that TTG nasal cavity retention time was so long. The cilia toxic test of toad showed that the formulation was safe. Animal experiments were approved by the Ethics Committee of Beijing Institute of Radiation Medicine, Academy of Military Medical Sciences and the experiments were conducted in accordance with relevant guidelines and regulations. The mice were randomly assigned into healthy group, model group and TTG group. The PTSD model of mice was established by single prolonged stress (SPS) and foot-shock method to generate anxiety and fear behavior. On the day 0 of TTG administration, SPS model mice were evaluated by the elevated plus maze (EPM). Percentages of open arm entries number (OE), latency of open arm entries (OL) and the residence time of open arm entries (OT) all indicated that the SPS model was successfully established. On the 7th day of TTG administration, TTG increased the OE and OT, decreased the OL of SPS mice. The feard behavior of mice in the foot-shock model was tested using conditioned fear box, 7 days of TTG treatment can reduce the freezing time of the mice obviously. The pathological changes of hippocampus, prefrontal cortex and amygdala were observed by H&E histological sections and c-fos immunohistochemical expression. The main influenced areas of PTSD were revealed to be the CA1 of hippocampus, prefrontal cortex and amygdala. All of the above indicated that TTG is a convenient, safe and effective drug for PTSD treatment, and will provide a new choice for clinical management of PTSD.
